NEW YORK (GenomeWeb) – 23andMe announced today that it has partnered with Celmatix, a personalized medicine company focused on fertility and women's health, to develop and validate biomarkers to diagnose and treat infertility.

Celmatix will contribute data from its discovery and annotation of more than 5,200 genetic biomarkers related to fertility, and 23andMe will add its genetic database and research community knowledge to the collaboration.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.